| P2093 | author name string | Julie K Andersen | |
| | Shankar J Chinta | |
| P2860 | cites work | Free radicals and antioxidants in normal physiological functions and human disease | Q21710698 |
| | Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry | Q24307861 |
| | Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 |
| | Alpha-synuclein in Lewy bodies | Q27860680 |
| | Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases | Q28269333 |
| | Perspectives on MAO-B in aging and neurological disease: where do we go from here? | Q28271492 |
| | Oxidative stress in neurodegeneration: cause or consequence? | Q28275946 |
| | Complex III releases superoxide to both sides of the inner mitochondrial membrane | Q28509539 |
| | Mice lacking alpha-synuclein are resistant to mitochondrial toxins | Q28511475 |
| | Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 |
| | Oxidative stress in Parkinson's disease | Q29618017 |
| | Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct | Q31029246 |
| | Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease | Q32035138 |
| | Redox imbalance | Q33206786 |
| | Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease | Q33220863 |
| | Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. | Q33941736 |
| | Bioenergetic approaches for neuroprotection in Parkinson's disease | Q33965184 |
| | Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection | Q33968464 |
| | Glutathione, oxidative stress and neurodegeneration | Q33994473 |
| | Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease | Q34015557 |
| | Pathoanatomy of Parkinson's disease | Q34035667 |
| | Oxidative stress and protein aggregation during biological aging | Q34348818 |
| | Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. | Q34394747 |
| | Oxidative stress and nitration in neurodegeneration: cause, effect, or association? | Q35047296 |
| | Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease | Q35728704 |
| | Does cellular iron dysregulation play a causative role in Parkinson's disease? | Q35824954 |
| | Genetic clues to the pathogenesis of Parkinson's disease | Q35844782 |
| | Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment | Q35891905 |
| | Abnormalities of the electron transport chain in idiopathic Parkinson's disease | Q69361952 |
| | Mitochondrial complex I deficiency in Parkinson's disease | Q69370277 |
| | Factors determining the selectivity of protein tyrosine nitration | Q73141785 |
| | Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease | Q79194214 |
| | ??? | Q64767196 |
| | Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases | Q35994672 |
| | Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia | Q36129202 |
| | Molecular pathophysiology of Parkinson's disease | Q36196507 |
| | Mitochondria take center stage in aging and neurodegeneration | Q36264218 |
| | Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. | Q36501983 |
| | Advances in the treatment of Parkinson's disease | Q36720216 |
| | Monamine oxidase inhibitors: current and emerging agents for Parkinson disease | Q36838868 |
| | Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease | Q36895132 |
| | Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. | Q36899240 |
| | In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. | Q40286709 |
| | Glutathione depletion in a midbrain-derived immortalized dopaminergic cell line results in limited tyrosine nitration of mitochondrial complex I subunits: implications for Parkinson's disease | Q40401735 |
| | G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage | Q40539190 |
| | Recent advances in pharmacological therapy of Parkinson's disease | Q40707933 |
| | Induction of alpha-synuclein aggregation by intracellular nitrative insult. | Q40776570 |
| | Presymptomatic detection of Parkinson's disease | Q40808143 |
| | Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity | Q40844291 |
| | Oxidative stress and the pathogenesis of Parkinson's disease | Q41262986 |
| | Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice | Q41593145 |
| | Parkinson's disease: a disorder due to nigral glutathione deficiency? | Q41628096 |
| | Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro | Q41646793 |
| | Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. | Q41740537 |
| | Striatal dopamine deficiency in Parkinson's disease: role of aging | Q41993839 |
| | Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy | Q42493792 |
| | Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus | Q42515011 |
| | Reduced intravenous glutathione in the treatment of early Parkinson's disease | Q42644977 |
| | Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure | Q43735123 |
| | Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration | Q43908040 |
| | Thioltransferase (glutaredoxin) mediates recovery of motor neurons from excitotoxic mitochondrial injury. | Q44156159 |
| | Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy | Q44214157 |
| | Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease | Q44386905 |
| | Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications | Q44511146 |
| | Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases | Q45138293 |
| | Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate | Q45227789 |
| | Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations | Q45302799 |
| | Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. | Q46377129 |
| | Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease | Q48127846 |
| | Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease | Q48140041 |
| | Apomorphine protects against MPTP-induced neurotoxicity in mice | Q48144127 |
| | Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid | Q48236376 |
| | Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase | Q48253577 |
| | Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. | Q48302165 |
| | Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients | Q48331251 |
| | Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. | Q48502457 |
| | Neural heme oxygenase-1 expression in idiopathic Parkinson's disease | Q48503937 |
| | Understanding Parkinson's disease | Q48825172 |
| | Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage. | Q48986485 |
| | Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. | Q54071317 |
| | Oxidative Stress: Damage to Intact Cells and Organs [and Discussion] | Q59151804 |
| | A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding | Q64380309 |
| | Sequestration of iron by Lewy bodies in Parkinson's disease | Q64771847 |
| | Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem | Q68456656 |
| | Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease | Q69356679 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 1362-1367 | |
| P577 | publication date | 2008-03-04 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Redox imbalance in Parkinson's disease | |
| P478 | volume | 1780 | |